Senesco Technologies to Present at 10th Annual Rodman & Renshaw Healthcare Conference
05 November 2008 - 12:00AM
PR Newswire (US)
NEW BRUNSWICK, N.J., Nov. 4 /PRNewswire-FirstCall/ -- Senesco
Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext US:
SNT) today announced that the Company will be presenting at the
10th Annual Rodman & Renshaw Healthcare Conference, which is
being held at the New York Palace Hotel from November 10-12, 2008.
Sascha P. Fedyszyn, Vice President, Corporate Development of
Senesco, will deliver the Company's corporate presentation on
Tuesday, November 11th, at 5:20 PM ET. Rodman & Renshaw is a
full-service investment bank dedicated to providing investment
banking services to companies that have significant recurring
capital needs due to their growth and development strategies. The
firm also provides research and sales and trading services to
institutional investor clients that focus on such companies. Since
2003, Rodman has been a leading investment banking firm to the
biotechnology sector, a capital intensive market segment, as well
as a leader in the private investment in public equity (PIPE) and
registered direct placements (RD) transaction markets. The
conference will feature innovative growth companies and investors
interested in such companies and will focus on firms within the
Life Science, Energy and Natural Resources sectors, as well as
firms based in promising Emerging Markets. Last year's conference,
which focused solely on Life Science firms, attracted more than
2,500 investors and industry attendees and included presentations
by more than 350 companies. About Senesco Technologies, Inc.
Senesco has initiated preclinical research to trigger or delay cell
death in mammals (apoptosis) to determine if its technology is
applicable in human medicine. Accelerating apoptosis may have
applications to the development of cancer treatments. Delaying
apoptosis may have applications to certain diseases such as
glaucoma, ischemia and arthritis, among others. Senesco takes its
name from the scientific term for the aging of plant cells:
senescence. The Company has developed technology that regulates the
onset of cell death. Delaying cell breakdown in plants extends
freshness after harvesting, while increasing crop yields, plant
size and resistance to environmental stress for flowers, fruits and
vegetables. In addition to its human health research programs, the
Company believes that its technology can be used to develop
superior strains of crops without any modification other than
delaying natural plant senescence. Senesco has partnered with
leading-edge companies engaged in agricultural biotechnology and
earns research and development fees for applying its
gene-regulating platform technology to enhance its partners'
products. Senesco is headquartered in New Brunswick, N.J. Certain
statements included in this press release are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Actual results could differ materially from
such statements expressed or implied herein as a result of a
variety of factors, including, but not limited to: the development
of the Company's gene technology; the approval of the Company's
patent applications; the successful implementation of the Company's
research and development programs and joint ventures; the success
of the Company's license agreements; the successful conversion of
the Company's letter of intent into a license agreement; the
acceptance by the market of the Company's products; success of the
Company's preliminary studies and preclinical research; competition
and the timing of projects and trends in future operating
performance, as well as other factors expressed from time to time
in the Company's periodic filings with the Securities and Exchange
Commission (the "SEC"). As a result, this press release should be
read in conjunction with the Company's periodic filings with the
SEC. The forward-looking statements contained herein are made only
as of the date of this press release, and the Company undertakes no
obligation to publicly update such forward-looking statements to
reflect subsequent events or circumstances. Company Contact:
Investor Relations Contact: Senesco Technologies, Inc. FD Bruce
Galton Brian Ritchie Chief Executive Officer () () (212) 850-5600
(732) 296-8400 DATASOURCE: Senesco Technologies, Inc. CONTACT:
Bruce Galton, Chief Executive Officer of Senesco Technologies,
Inc., +1-732-296-8400, , or Brian Ritchie of FD, +1-212-850-5600,
Web Site: http://www.senesco.com/
Copyright